menu

FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval

    FDA experts discuss the first approval of a cancer treatment based on a common biomarker rather primary tumor location.
    • Overview

      The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.

      Released May 30, 2017.

    Facebook Comments

    You must be in to display playlists.

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.